Background: High-dose therapy/stem cell rescue (HDT/SCT) is offered to most younger patients with multiple myeloma (MM) patients as part of the initial therapy. However, the role of HDT/SCT in the management of patients with MM is controversial. Aim: The aim of this study was to compare HDT/SCT and continued conventional chemotherapy in MM patients responding to the initial treatment. Patients and Methods: From May 1994 to October 1999, 216 patients (122M/94F, median age 56 yrs, stage II or III, ECOG < 3) were registered. The initial chemotherapy consisted of 4 courses of alternating BVMCP/VBAD. Responding patients received either 8 additional courses of BVMCP/VBAD (arm A) or intensification with HDT/SCT -melphalan 140 mg/m2/TBI 12 Gys or melphalan 200 mg/m2 (arm B). Maintenance treatment consisted of alpha-interferon and dexamethasone in both arms. Results: One-hundred and eighty five patients responded to initial chemotherapy (CR: 15%, PR: 68%, and MR: 17%). Twenty-one of these responding patients were not randomized due to different reasons. Among the 164 randomized patients 83 were allocated to continued chemotherapy and 81 to HDT/SCT. The degree of initial response as well as prognostic features did not differ in both groups. The results were updated as of November 15, 2002 after a median follow-up of 49 months from the initiation of treatment and analyzed on an intention-to-treat basis. CR (negative electrophoresis) was significantly higher in the HDT/SCT arm (30 vs. 11%, p=0.002). However, PFS was not significantly different between HDT/SCT and conventional chemotherapy (median, 43 vs. 34 mos; p=NS) and the OS was similar in both groups (median, 62 vs. 56 mos.; p=NS) . Conclusions: This study shows that HDT/SCT intensification significantly increases complete remission rate but has no significant impact on PFS and OS in myeloma patients responding to initial chemotherapy.
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CD34 + selection of autologous transplants in patients with newly diagnosed myeloma: final report of an EBMT phase III randomized study J.H. Bourhis, Y. Bouko, S. Koscielny, H. Greinix, G. Derigs, G. Salles, W. Feremans, M. Bakkus, J. Apperley, D. Samson, G. Gahrton, J. Pico, H. Goldschmidt on behalf of the EBMT Multiple Myeloma Subcommittee CD34+ selection of PBSC has been used in MM as a mean to reduce relapse linked with tumor cells contamination and thus improving outcome. However, a clinical benefit has not been demonstrated at the onset of this study. From May 1995 to November 1999, 127 pts from 17 EBMT centers with newly diagnosed advanced MM were included into this phase III trial and 112 pts are analysed. Responders to 3 cycles of VAD were randomized to receive a CD34+ selected graft (arm A, n=55) or an unselected graft (arm B, n=57). PBPC were harvested following mobilization with cyclophosphamide 4g/m² and G-CSF (Filgrastim). Conditioning regimen in both arms was TBI and melphalan 140 mg/m². CD34+ selection was performed in arm A using the CellPro Ceprate-SC device and resulted in a median purity of 88.5% and yield of 63%. Molecular analysis showed a median tumor cell depletion of 1.93 log (0.87-5.2). The médian number of CD34+ cells reinfused was 7.2x106 CD34 cells/kg (1.4 -50.4) in arm A and 14.4x106 CD34 cells/kg (1.8-99.2) in arm B. The median time to neutrophil engraftment (ANC>O.5x109/l) was 10 days in arm A (8-14) and 10 days in arm B (8-21). The median time to platelets engraftment (plts>20x109/l) was 11 days in both arms but one patient in arm A never reached 20x109/l platelets without supportive transfusions. 13 episodes of serious infections between the time of neutrophil engraftment and day 100 were reported in arm A compared to only 1 in arm B. All the infections were viral except 1 bacterial and 1 protozoal. For 3 patients in arm A, these infections were fatal (parainfluenza, CMV and myocarditis of infective etiology). The overall transplant mortality was 2.7% (3 patients in arm A). There was no significant difference in CR rate at 1 year as defined by EBMT/IBMTR/ABMTR criteria (16% in arm A and 15% in arm B). There is so far no significant difference in EFS and OS. Median follow-up is 47 months in both arms. Probability of OS at 3 years is 71% in arm A and 81.5% in arm B. The 3 year relapse risk is 54.05% in arm A vs. 30.5% in arm B. In summary, CD34+ selection resulted in a 1.9 tumor cell depletion without delay in hematological recovery. However, long term follow up analysis of these patients shows no significant clinical benefit for progression free survival. Moreover, the increased incidence of bacterial and viral life threatening infections in the CD34+ selected arm, similar to those for allogeneic BMT recipients, legitimate systematic prophylaxis regimens and raise clinical concerns . Altogether, these results suggest new approaches in CD34+ selection to circumvent immune recovery delay.
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10-year survival in myeloma: a new endpoint for testing potentially curative strategies? R. Powles, B. Sirohi, S. Singhal, S. Kulkarni, R. Saso, C. Horton, S. Sankpal, J. Treleaven, J. Mehta (Sutton, UK) We have previously shown that patients with myeloma who survive longer than 10 years in complete remission (CR) appear to be on a plateau of survival in which life span and quality of life might be normal (Powles et al, Blood 2000: 96; 2215a) . 10-y survival might therefore become increasingly important as an endpoint when testing new treatment strategies, but probably requires the platform o f CR for effective treatment. We have studied 167 patients (median age 52 y, range 30-68; 63F, 104M; 60% IgG, 81% stage III disease) with newly-diagnosed myeloma who were planned to receive sequential therapy with a minimum follow-up of 10 y (all diagnosed before 1993) to look for diagnostic criteria of survival for 4, 5 and 10 y. The median albumin was 35 g/L (15-52), median B2M 3.9 mg/L (0.6-52), median creatinine 92 micmol/L (45-1463). There were differences in the demographic features for 4, 5 and 10-y survival. 72/167 (43%) survived for < 4 years, 50% for < 5 years and 75% for < 10 years. 34 (20%) patients survived for longer than 10 years. For 4 -y survival B2M, Haemoglobin, Calcium, Creatinine, performance status, age, Urea, albumin and marrow plasma c ell percentage were statistically significant in the univariate analysis and for 5-y survival the variables were B2M, Haemoglobin, Calcium, Creatinine, albumin and marrow plasma cell percentage. The statistically significant variables for 10-y survival were B2M, Hb, Calcium, Creatinine, Marrow plasma cell percentage, CR with infusional chemotherapy and those who received high-dose therapy. Patients with pre-therapy B2M <3 and age < 55 y (n=39) had a median OS of 9.1 y (95% CI 6.5-11.5) and 10-y survival of 43.4% [figure] . Post-therapy, patients with the same criteria but if they had chemosensitive disease post infusional chemotherapy and received high-dose therapy (n=28), the median OS was 10.4 years compared to 3.6 years in those who did not fulfill all the criteria. 10-y survival should be an endpoint incorporated in all future studies because treatment strategies to improve this may be different from the ones already in use i.e treatments for consolidating remission as done in leukaemics.
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Stem cell transplantation from unrelated donors after a reduced intensity conditioning in patients with advanced multiple myeloma N. Kröger, H. Sayer, R. Schwerdtfeger, M. Kiehl, A. Nagler, A. Shimoni, H. Renges, T. Zabelina, F. Ayuk, B. Fehse, G. Wittkowsky, N. Schmitz, A. Zander (Hamburg, Jena, Wiesbaden, Idar-Oberstein, D; Tel Hashomer, IL) We report the feasibility of unrelated stem cell transplantation in 31 patients with advanced stage II/III multiple myeloma after a reduced intensity conditioning regimen consisting of fludarabine, melphalan (100-140 mg/m²) and anti-thymocyte globulin (ATG: 3x 10-20mg/kg). The median patient age was 52 years (range 31-61). All patients had received at least one prior autologous transplantation, in 16 cases as part of an autologous-allogeneic tandem protocol. Disease status prior allogeneic transplantation was: CR: n=1; PR: n=14 ; MR: n=1; NC: n=6; PD: n=9. No graft failure was observed. At day 40 complete donor chimerism was detected in all evaluable patients. Grade II-IV acute Graft versus host disease (GvHD) was seen in 17 (57%) , while severe grade III/IV GvHD was observed in 7 patients (23%). Six patients (29%) developed chronic GvHD, but only two patients (12%) experienced extensive chronic GvHD. The estimated probability of non-relapse mortality at 1 year was 27%. After allografting 48% of the patients achieved a complete remission. The 2 years estimated overall and progression-free survival is 46% (95% CI: 25 -67%) and 36% (95% CI: 16 -56%), respectively. A shorter overall survival was seen in patients who already experienced relapse to prior autograft (24% vs 75%, p=0.01). Dose-reduced conditioning with pretransplant ATG followed by unrelated stem cell transplantation provides durable engraftment and donor chimerism, reduces substantially the risk of transplant related organ toxicity and induces high remission rates.
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Autologous transplantation in primary plasma cell leukemia M. Drake, C. Morris, A. Hagman, T. Lopponen, B. Bjorkstrand, G. 
Gahrton, J. Apperley Myeloma Subcommittee of the Chronic Leukaemia Working Party of the EBMT
Primary plasma cell leukaemia (PCL) is a rare disorder, representing less than 5% of malignant plasma cell disease and characterised by plasma cells circulating in the peripheral blood. The disorder is rapidly progressive with a median survival of 8-12 months with conventional chemotherapy. Prolonged survival has been reported with autologous haematopoietic transplantation (ASCT) though outcome may be inferior to patients with multiple myeloma, as reported in our previous study of 56 autografted patients with PCL. Here, we report an EBMT registry study of an extended series of 135 patients with PCL and 9887 patients with multiple myeloma undergoing first ASCT. Patient groups were not significantly different with regard to gender, performance status pre-transplantation or use of TBI and graft-type (marrow, peripheral blood or both). 14.2, 21.3 and 64.5% of myeloma patients and 4.3, 17.0 and 78.7% of PCL patients were Stage I, II or III at diagnosis (p = 0.077). PCL patients comprised a significantly younger group at diagnosis (51.9 v 53.6 years, p = 0.022) and transplantation (52.7 v 55.1 years, p = 0.002) and were transplanted a median of 6.57 months from diagnosis (myeloma patients 8.25 months, p = 0.000). Higher levels of creatinine (114 v 91 micro mol/l, p = 0.021)and lower haemoglobin (8.75 v 10.9 g/dl, p = 0.000) were seen at diagnosis, but no difference in M protein, calcium or albumen levels. Beta 2 microglobulin was raised at diagnosis in 71.8 v 30.8% of PCL v multiple myeloma patients (p = 0.000) while there were 32% and 28.8% of PCL patients and 16.1% and 15% of myeloma patients in complete remission at mobilisation (p = 0.074) and transplant conditioning (p = 0.000) respectively. Median survival of PCL patients post-ASCT was 21 months (95% confidence intervals 6 -36 months), markedly inferior to that of myeloma patients which was 55 months (52 -58 months, p = 0.000). These findings confirm a significantly poorer prognosis after ASCT in PCL compared to multiple myeloma despite likely pre-selection of a relatively fit population through early morbidity and mortality from initial chemotherapy.
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Lack of CD45 expression has a strong prognostic value in patients with multiple myeloma receiving high-dose therapy P. Moreau, N. Robillard, H. Avet-Loiseau, N. Morineau, D. Pineau, N. Milpied, B. Mahé, M. Vigier, M.-J. Rapp, J.-L. Harousseau, R. Bataille (Nantes, F) CD45 is brightly expressed in normal immature proliferative plasma cells (PC) and weakly expressed in mature resting PC in the bone marrow. In multiple myeloma (MM), proliferative malignant PC retain a bright expression of CD45 (Joshua, Br J Haematol 1996; 94:76) and as in normal bone marrow, CD45 expression is low in the less proliferative myeloma cells. However, as opposed to normal PC, some myeloma cells have lost CD45 expression, especially those circulating in the peripheral blood, in relation to disease severity (Witzig, Cytometry 1996; 26:113 -Schneider Br J Haematol 1997; 97:56) . These data suggest that the lack of CD45 expression could be 1)observed on the most malignant myeloma cells and 2) of prognostic value in patients with MM when CD45neg myeloma cells are dominant within the myeloma clone. Thus we have evaluated the CD45 expression using flow cytometry on bone marrow PC in 67 newly diagnosed MM patients receiving highdose therapy (HDT) and tested its prognostic value, especially in comparison with that of serum beta2microglobulin (b2m), chromosome 13 deletion (Del13) and the combination of these 2 variables in the prognostic index recently described by Facon (Blood 2001; 97:1566) . Patients were 36 males and 31 females, median age 58 years (33-70). They were divided into 2 groups according to the level of CD45 expression on tumor cells: 20 patients were CD45neg (group A) and 47 had bright to low CD45 expression (group B). The 2 groups were identical regarding clinical and biological features at diagnosis (age, sex, isotype, disease stage, b2m, albumine, Ca, creatinine, labelling index, Del13). All patients received HDT followed by autologous stem cell transplantation as part of frontline treatment and disease status and conditioning regimens were also identical in both groups. The single parameter that influenced overall survival (OS) in this cohort of patients was CD45 expression on myeloma cells. The OS rate from diagnosis was 31.2% at 6 years in group A (median 42 months) vs 61.4% in group B (median not reached, p = .02). Conclusions: 1 -30% of the patients with MM are CD45neg at diagnosis 2 -CD45 expression has a strong prognostic value, better than b2m, Del13, and better than the staging system combining b2m and Del13, which has to be confirmed in a larger prospective cohort of patients 3 -CD45 expression could reflect the intrinsic malignancy of the myeloma clone.
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Autologous and allogenic transplantation for Waldenström's macroglobulinemia
O. Tournilhac, V. Leblond, R. Tabrizi, R. Gressin, D. Senecal, N. Milpied, B. Cazin, M. Divine, A. Sadoun, J.-Y. Cahn, B. Pignon, B. Desablens, G. Manhes, J.-O. Bay, P. Travade (ClermontFerrand, Paris, Bordeaux, Grenoble, Tours, Nantes, Lille, Creteil, Poitiers, Besançon, Reims, Amiens, F) Waldenström macroglobulinemia (WM)) is a rare and incurable disorder with a frequently prolonged course. Chlorambucil remains a standard therapeutic option, nucleoside analogues can effect high response rate and results with rituximab are promising. Nevertheless the impact on survival of such treatments is uncertain. High dose therapy (HDT) followed by stem cell transplantation can induce very good results in close disorders as multiple myeloma, chronic lymphocytic leukemia or indolent lymphomas but to date published data are still limited in WM. We present a retrospective multicentric study of 27 WM patients who underwent 19 autologous and 10 allogenic transplantations. Median duration between diagnosis and transplantation was 36 months. At time to transplantation, 66% patients had been heavily pretreated (3 or more treatment lines) and 72% had a chemosensitive disease. In the autologous transplantation group (median age 54 yearsold) HDT induced a 95% response rate (RR) including 3 CR, 7 very good PR and 8 PR. With a median follow-up of 18,5 months, 12 patients are alive at 10-84 months and 8 are free of progression at 10-34 months. Nine patients relapsed at 1 -25 months. Six patients died at 3 -17 months, 4 from disease progression, 1 from toxicity (acute myeloid leukemia at 3 months) and 1 following a second (allogenic) transplantation administered for early relapse. In the allogenic group (median age 46 years-old), transplantation was preceded by HDT in 9 patients and by non myeloablative regimen in 1. The RR was 80% including 5 CR and 2 very good PR. With a median follow-up of 23 months, 6 patients are alive and 5 of them are free of progression at 3-76 months. Three patients had an early relapse at 2, 3 and 10 months and 1 had a late biological relapse at 36 months but is alive and free of treatment at 53 months. Four patients died at 3, 11, 12 and 18 months all from toxicity leading TRM to 40%. HDT followed by autologous transplantation is feasible in WM even in heavily pretreated patients and up to 60 years old with some prolonged response but high relapse rate. Conversely, allogenic transplantation is more toxic but likely induces a graft versus WM effect and should be considered as a curative alternative. The development of non myeloablative conditioning regiments seems to be promising in this setting.
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Prognostic factors at the time of autotransplantation with 200 mg/m2 melphalan: a single center study of 451 myeloma patients B. Sirohi, R. Powles, S. Singhal, S. Kulkarni, C. Horton, M. Stephens, C. Rudin, S. Sankpal, J. Mehta (Sutton, UK) High-dose melphalan 200mg/m2 (HDM200)has been shown to be the most optimal regimen for consolidation therapy in patients with myeloma (MM) (Moreau P et al Blood 2002; 99:731-5) . We present the largest series of MM patients treated with HDM200 and a single unpurged autograft. 451 patients (31-75 y, median 53; 154F,297M; 73% stage III;94% IgG; 66% >=2 bone lesions) were treated from 1985 to 2001.. The median B2M was 2.3mg/L (0.1-54.6), median creatinine 81 micromol/L (43-732), median albumin 39g/L (22-48). 49% presented after induction elsewhere and 51% were untreated. Therapy was: Induction (VAMP/C-VAMP for untreated patients) to 1 cycle beyond maximum response followed by Marrow or G-CSF-mobilized PBSC harvest and HDM200 followed by Interferon-alpha2b. Before HDM200, 75 (17%) patients were in CR, 286 (63%) in PR and 90 (20%) were NR. A further 192 (43%) went into CR during HDM200 so that the total CR rate after HDM was 59% (266/451). The overall response rate was 407/451 (91%).27 (5.9%) patients died at a median of 21 days.The median OS for the whole group was 5.7 years (95% CI-5.1-6.8) and the median EFS was 2.3 years (95% CI-2.1-2.7). 246/451 (55%) patients have relapsed at a median of 2.8 years (95% CI-2.3-3.3). Only two patients developed myelodysplasia 2 and 8 years after HDM200. The preautotransplantation biologic variables chosen to be included in the multivariate analysis were Age, sex, calcium , B2M, albumin, creatinine , immunologic subtype of myeloma (IgG/IgA vs others), performance status (0 vs rest according to the Karnofsky scale), disease stage at the time of HDM200 (CR vs rest). Cox analysis showed that patients >=53 years (RR 1.6, P<0.0001), albumin <=39mmol/L (RR 0.6, P<0.0001), B2M >2.3 (RR 1.5, P=0.006) had a significantly worse OS, those not in CR at the time of HDM200 (RR 0.7, P=0.03) had a higher probability of relapsing; those not in CR at HDM200 (RR 0.7, P=0.004), Age >=53 years (RR 1.4, P=0.007) and albumin <=39 (RR 0.8, P=0.04) had a significantly worse EFS. Given the importance of achieving CR at the time of high-dose therapy, intensification of induction treatment may be of benefit and makes the case for administering induction therapy to maximum response. No other factor influenced relapse. We conclude that HDM200 results in excellent outcome in myeloma and should be considered as the standard of care and this also raises questions about the use of tandem-autotransplantation as routine therapy.
